Search Results - "Burkart, Jarred"

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study by Martínez Chanzá, Nieves, Xie, Wanling, Asim Bilen, Mehmet, Dzimitrowicz, Hannah, Burkart, Jarred, Geynisman, Daniel M, Balakrishnan, Archana, Bowman, I Alex, Jain, Rohit, Stadler, Walter, Zakharia, Yousef, Narayan, Vivek, Beuselinck, Benoit, McKay, Rana R, Tripathi, Abhishek, Pachynski, Russell, Hahn, Andrew W, Hsu, JoAnn, Shah, Sumit A, Lam, Elaine T, Rose, Tracy L, Mega, Anthony E, Vogelzang, Nicholas, Harrison, Michael R, Mortazavi, Amir, Plimack, Elizabeth R, Vaishampayan, Ulka, Hammers, Hans, George, Saby, Haas, Naomi, Agarwal, Neeraj, Pal, Sumanta K, Srinivas, Sandy, Carneiro, Benedito A, Heng, Daniel Y C, Bosse, Dominick, Choueiri, Toni K, Harshman, Lauren C

“…Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib…”
Get full text

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort by Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, Walker, Paul R.

“…Background Immune-related adverse events (irAEs) comprise a distinct spectrum of auto-inflammatory manifestations triggered due to immune checkpoint inhibitors…”
Get full text

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications by Spakowicz, Daniel, Hoyd, Rebecca, Muniak, Mitchell, Husain, Marium, Bassett, James S, Wang, Lei, Tinoco, Gabriel, Patel, Sandip H, Burkart, Jarred, Miah, Abdul, Li, Mingjia, Johns, Andrew, Grogan, Madison, Carbone, David P, Verschraegen, Claire F, Kendra, Kari L, Otterson, Gregory A, Li, Lang, Presley, Carolyn J, Owen, Dwight H

“…The microbiome has been shown to affect the response to Immune Checkpoint Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we…”
Get full text

Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy by Johns, Andrew C., Yang, Mike, Wei, Lai, Grogan, Madison, Patel, Sandipkumar H., Li, Mingjia, Husain, Marium, Kendra, Kari L., Otterson, Gregory A., Burkart, Jarred T., Spakowicz, Daniel, Hoyd, Rebecca, Owen, Dwight H., Presley, Carolyn J.

“…Background and objectives Medical comorbidities (MC) are highly prevalent among patients with cancer and predict worse outcomes for traditional therapies. This…”
Get full text

Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer by Johns, Andrew C., Wei, Lai, Grogan, Madison, Hoyd, Rebecca, Bridges, John F.P., Patel, Sandipkumar H., Li, Mingjia, Husain, Marium, Kendra, Kari L., Otterson, Gregory A., Burkart, Jarred T., Rosko, Ashley E., Andersen, Barbara L., Carbone, David P., Owen, Dwight H., Spakowicz, Daniel J., Presley, Carolyn J.

“…Despite growing evidence that checkpoint inhibitor immunotherapy (IO) toxicity is associated with improved treatment response, the relationship between…”
Get full text

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort by Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, Walker, Paul R.

“…The original version of this article unfortunately contained a mistake. The second sentence of the section “irAEs and ICI efficacy” should read as…”
Get full text

Subnuclear development of the zebrafish habenular nuclei requires ER translocon function by Doll, Caleb A., Burkart, Jarred T., Hope, Kyle D., Halpern, Marnie E., Gamse, Joshua T.

“…The dorsal habenular nuclei (Dh) of the zebrafish are characterized by significant left–right differences in gene expression, anatomy, and connectivity…”
Get full text

Formation of the asymmetric pineal complex in zebrafish requires two independently acting transcription factors by Snelson, Corey D., Burkart, Jarred T., Gamse, Joshua T.

“…The pineal complex of zebrafish consists of a pineal organ and a left‐sided parapineal organ. Mutation of the floating head (flh) gene, which encodes a…”
Get full text

268 Atonal Homolog 1 (ATOH1) is Essential for Growth and Differentiation Effects of Notch/γ Secretase Inhibitors on Normal and Cancerous Intestinal Epithelial Cells by Kazanjian, Avedis, Noah, Taeko K, Brown, Douglas, Burkart, Jarred T, Shroyer, Noah F

Get full text

802 Atonal Homolog 1 Is a Tumor Suppressor in Colorectal Cancers by Kazanjian, Avedis, Burkart, Jarred T, Shroyer, Noah F

Get full text

Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations by Ajam, Amna, Ozkan, Efe, Zhao, Weiqiang, Shilo, Konstantin, Burkart, Jarred, Otterson, Gregory A.

“…The case reported is a young “light” ex-smoker who initially had a localized adenosquamous carcinoma bearing an epidermal growth factor receptor (EGFR)…”
Get full text

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers by Li, Mingjia, Spakowicz, Daniel, Burkart, Jarred, Patel, Sandip, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Carbone, David P., Verschraegen, Claire F., Presley, Carolyn J., Otterson, Gregory A., Kendra, Kari, Owen, Dwight H.

“…Background The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients with advanced cancers treated with immune checkpoint inhibitors…”
Get full text

Atonal Homolog 1 Is Required for Growth and Differentiation Effects of Notch/γ-Secretase Inhibitors on Normal and Cancerous Intestinal Epithelial Cells by Kazanjian, Avedis, Noah, Taeko, Brown, Douglas, Burkart, Jarred, Shroyer, Noah F

“…Background & Aims The atonal homolog 1 (Atoh1) transcription factor is required for intestinal secretory (goblet, Paneth, enteroendocrine) cell…”
Get full text

Association of medical comorbidities and cardiovascular disease with toxicity and survival in patients receiving checkpoint inhibitor immunotherapy by Johns, Andrew, Wei, Lai, Grogan, Madison, Patel, Sandipkumar, Li, Mingjia, Husain, Marium, Kendra, Kari Lynn, Otterson, Gregory Alan, Burkart, Jarred Thomas, Owen, Dwight Hall, Presley, Carolyn J

“…Abstract only 7039 Background: Checkpoint inhibitor immunotherapy (IO) is widely used to treat advanced cancer in pts. with medical comorbidities (MC), but the…”
Get full text

Neutrophil to lymphocyte ratio, PD-L1 expression, and survival in patients with advanced non-small cell lung cancer receiving first-line immune checkpoint inhibitor therapy by Li, Mingjia, Zhao, Songzhu, Spakowicz, Daniel, Burkart, Jarred Thomas, Patel, Sandip H., Husain, Marium, He, Kai, Bertino, Erin Marie, Shields, Peter G., Wei, Lai, Presley, Carolyn J, Otterson, Gregory Alan, Owen, Dwight Hall

“…Abstract only 46 Background: Neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients with various types of cancer, including those who are…”
Get full text

Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration by Naqash, Abdul Rafeh, Owen, Dwight Hall, Ricciuti, Biagio, Toi, Yukihiro, Chiari, Rita, Sharma, Nitika, Patel, Sandip H., Sugawara, Shunichi, Cherry, Cynthia R., Burkart, Jarred Thomas, De Giglio, Andrea, Sugisaka, Jun, Bowling, Mark, Otterson, Gregory Alan, Walker, Paul R.

“…Abstract only 118 Background: Immune-related adverse events (irAEs) due to immune-checkpoint inhibitors (ICI) can lead to significant morbidity. Immune…”
Get full text

Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy by Spakowicz, Daniel, Husain, Marium, Tinoco, Gabriel, Patel, Sandip H., Burkart, Jarred Thomas, Verschraegen, Claire F., Kendra, Kari Lynn, Hoffman, Sarah, Philippon, Jennifer, Quiroga, Dionisia Marie, Otterson, Gregory Alan, Owen, Dwight Hall

“…Abstract only 94 Background: The response to Immunotherapy (IO) is known to be affected by concomitant medications including corticosteroids and antibiotics…”
Get full text

Changes in lymphocyte/monocyte ratio, prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitor by Patel, Sandip H., Li, Mingjia, Zhao, Songzhu, Wei, Lai, Burkart, Jarred Thomas, Husain, Marium, He, Kai, Bertino, Erin Marie, Shields, Peter G., Carbone, David Paul, Verschraegen, Claire F., Otterson, Gregory Alan, Kendra, Kari Lynn, Spakowicz, Daniel, Presley, Carolyn J, Owen, Dwight Hall

“…Abstract only 3047 Background: Immunosuppressive factors within the tumor microenvironment (TME) pose a barrier to response to treatment with immune checkpoint…”
Get full text

Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer? by Johns, Andrew, Grogan, Madison, Hoyd, Rebecca, Bridges, John F.P, Wei, Lai, Patel, Sandipkumar, Li, Mingjia, Husain, Marium, Kendra, Kari Lynn, Otterson, Gregory Alan, Burkart, Jarred Thomas, Rosko, Ashley Elizabeth, Andersen, Barbara L., Carbone, David Paul, Owen, Dwight Hall, Spakowicz, Daniel, Presley, Carolyn J

“…Abstract only 6580 Background: There is growing evidence that checkpoint inhibitor immunotherapy (IO) toxicity is associated with improved treatment response…”
Get full text

Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving immunotherapy by Spakowicz, Daniel, Li, Mingjia, Hoyd, Rebecca, Burkart, Jarred Thomas, Patel, Sandip H., Husain, Marium, He, Kai, Presley, Carolyn J, Bertino, Erin Marie, Shields, Peter G., Carbone, David Paul, Shah, Hiral A., Tinoco, Gabriel, Folefac, Edmund, Bhateja, Priyanka, Verschraegen, Claire F., Otterson, Gregory Alan, Li, Lang, Kendra, Kari Lynn, Owen, Dwight Hall

“…Abstract only e18201 Background: Neutrophil to Lymphocyte Ratio (NLR) is prognostic for cancer patients treated with immune checkpoint inhibitors (ICI). We…”
Get full text